Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People with T2D (SURPASS-2)

Investigators explored changes in biomarkers of beta-cell function and insulin sensitivity and efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide.